PubRank

Gudrun Göhring

Author PubWeight™ 75.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010 4.76
2 Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011 3.17
3 TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011 2.88
4 Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012 2.69
5 Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010 2.38
6 Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011 2.26
7 Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2009 2.23
8 Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010 2.11
9 Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med 2014 2.00
10 The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2010 1.96
11 Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011 1.79
12 Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. Blood 2012 1.68
13 Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011 1.65
14 Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013 1.62
15 Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010 1.56
16 IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010 1.32
17 Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009 1.31
18 Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2011 1.30
19 Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2013 1.12
20 The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 2013 1.11
21 Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol 2006 1.00
22 Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010 1.00
23 Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2014 0.99
24 P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 2004 0.99
25 Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 2008 0.98
26 FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica 2011 0.98
27 Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Ann Hematol 2012 0.97
28 Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Res 2011 0.96
29 Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes*. Eur J Haematol 2009 0.95
30 Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol 2011 0.95
31 Concise review: managing genotoxicity in the therapeutic modification of stem cells. Stem Cells 2011 0.94
32 Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 2010 0.94
33 B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol 2006 0.94
34 Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood 2014 0.93
35 Clonal heterogeneity in childhood myelodysplastic syndromes--challenge for the detection of chromosomal imbalances by array-CGH. Genes Chromosomes Cancer 2010 0.92
36 Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Ann Hematol 2012 0.91
37 Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model. Blood 2012 0.88
38 Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res 2009 0.87
39 Prenatal diagnosis of an epignathus associated with a 49,XXXXY karyotype--a case report. Fetal Diagn Ther 2008 0.87
40 Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation. Blood 2009 0.86
41 Update on cytogenetic and molecular changes in myelodysplastic syndromes. Leuk Lymphoma 2011 0.86
42 Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. Ann Hematol 2010 0.86
43 MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro. J Pediatr Surg 2002 0.85
44 Induced pluripotent stem cells generated from adult bone marrow-derived cells of the nonhuman primate (Callithrix jacchus) using a novel quad-cistronic and excisable lentiviral vector. Cell Reprogram 2012 0.84
45 Mesenteric chloroma with t(16;16) followed by acute myelomonocytic leukemia with clonal evolution. Cancer Genet Cytogenet 2007 0.84
46 Constitutional trisomy 8p11.21-q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia. Br J Haematol 2011 0.84
47 High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 2008 0.84
48 Genetic instability of modified stem cells - a first step towards malignant transformation? Am J Stem Cells 2013 0.84
49 Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease. Genes Chromosomes Cancer 2008 0.83
50 Fast and efficient multitransgenic modification of human pluripotent stem cells. Hum Gene Ther Methods 2014 0.82
51 A tumor-derived population (SCCOHT-1) as cellular model for a small cell ovarian carcinoma of the hypercalcemic type. Int J Oncol 2012 0.81
52 Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study. Leuk Res 2009 0.81
53 Novel CHD7 mutations contributing to the mutation spectrum in patients with CHARGE syndrome. Eur J Med Genet 2010 0.81
54 Induction of pluripotent stem cells from a cynomolgus monkey using a polycistronic simian immunodeficiency virus-based vector, differentiation toward functional cardiomyocytes, and generation of stably expressing reporter lines. Cell Reprogram 2012 0.81
55 Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML. Ann Hematol 2010 0.80
56 TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns. Genes Chromosomes Cancer 2014 0.79
57 No evidence for ITSN1 loss in a patient with mental retardation and complex chromosomal rearrangements of 21q21-21q22. Leuk Res 2013 0.79
58 Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype. BMC Genomics 2014 0.78
59 Cryptic t(15;17) in a patient with AML M3 and a complex karyotype. Cancer Genet Cytogenet 2007 0.78
60 Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol 2014 0.77
61 Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes. Cancer Genet 2013 0.76
62 Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Ann Hematol 2013 0.76
63 In vitro modelling of familial amyloidotic polyneuropathy allows quantitative detection of transthyretin amyloid fibril-like structures in hepatic derivatives of patient-specific induced pluripotent stem cells. Biol Chem 2017 0.75
64 Acute lymphoblastic leukemia in a patient with constitutional chromosome 1pter-p36.31 duplication and 1q43-qter deletion. J Pediatr Hematol Oncol 2012 0.75
65 Mutation analysis of the HAX1 gene in childhood myelodysplastic syndrome. Br J Haematol 2009 0.75
66 Identification of a Cryptic Insertion ins(11;X)(q23;q28q12) Resulting in a KMT2A-FLNA Fusion in a 13-Month-Old Child with Acute Myelomonocytic Leukemia. Cytogenet Genome Res 2017 0.75
67 Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D. Am J Med Genet A 2012 0.75
68 Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. Ann Hematol 2014 0.75
69 Extramedullary relapse of therapy-related myelodysplastic syndrome after donor leukocyte infusion. Ann Hematol 2007 0.75